Compare PESI & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PESI | OABI |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | United States |
| Employees | N/A | 89 |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 243.9M | 225.9M |
| IPO Year | 1996 | N/A |
| Metric | PESI | OABI |
|---|---|---|
| Price | $12.19 | $1.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 195.7K | ★ 253.6K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.61 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $642,000.00 | N/A |
| Revenue This Year | $34.62 | $52.42 |
| Revenue Next Year | $77.02 | $64.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.07 | $1.22 |
| 52 Week High | $16.50 | $2.22 |
| Indicator | PESI | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 50.19 | 29.50 |
| Support Level | $11.01 | $1.32 |
| Resistance Level | $12.37 | $1.86 |
| Average True Range (ATR) | 0.71 | 0.08 |
| MACD | 0.20 | -0.01 |
| Stochastic Oscillator | 86.11 | 0.00 |
Perma-Fix Environmental Services Inc is a provider of both nuclear services and the management of nuclear and mixed waste. The company operates through two segments: The treatment segment offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.